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Abstract
Traumatic spinal cord injury (SCI) has widespread physiological effects beyond the disruption of 
sensory and motor function, notably the loss of normal autonomic and cardiovascular control. 
Injury at or above the sixth thoracic spinal cord segment segregates critical spinal sympathetic 
neurons from supraspinal modulation which can result in a syndrome known as autonomic 
dysreflexia (AD). AD is defined as episodic hypertension and concomitant baroreflex-mediated 
bradycardia initiated by unmodulated sympathetic reflexes in the decentralized cord. This 
condition is often triggered by noxious yet unperceived visceral or somatic stimuli below the 
injury level and if severe enough can require immediate medical attention. Herein, we review the 
pathophysiological mechanisms germane to the development of AD, including maladaptive 
plasticity of neural circuits mediating abnormal sympathetic reflexes and hypersensitization of 
peripheral vasculature that collectively contribute to abnormal hemodynamics after SCI. Further, 
we discuss the systemic effects of recurrent AD and pharmacological treatments used to manage 
such episodes. Contemporary research avenues are then presented to better understand the relative 
contributions of underlying mechanisms and to elucidate the effects of recurring AD on 
cardiovascular and immune functions for developing more targeted and effective treatments to 
attenuate the development of this insidious syndrome following high-level SCI.
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1. Introduction
In addition to motor and sensory deficits, traumatic spinal cord injury (SCI) causes a 
constellation of interrelated autonomic and cardiovascular abnormalities. Cardiovascular 
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complications secondary to SCI are among the leading causes of mortality and morbidity in 
this population, underscoring the necessity to understand and properly manage resultant 
comorbidities (Cragg et al., 2013; Garshick et al., 2005; Myers et al., 2007; Sabre et al., 
2013). In humans, SCI at or above the sixth thoracic (T6) spinal cord segment often results 
in the development of a potentially life-threatening syndrome called autonomic dysreflexia 
(AD). AD is clinically defined as acute hypertension generated by unmodulated sympathetic 
reflexes below the injury level that is often accompanied by baroreceptor-mediated 
bradycardia, which provides short-term control of blood pressure (Karlsson, 1999). In 
response to hypertension, the baroreflex system lowers blood pressure by reducing heart rate 
and decreasing activity of vasoconstrictor sympathetic preganglionic neurons (SPN) located 
throughout the thoracolumbar spinal cord that regulate peripheral vascular resistance. 
However, while vagal parasympathetic innervation of the heart remains intact after SCI, the 
disruption of descending vasomotor pathways to SPN produces an incomplete compensatory 
decrease in peripheral vascular resistance so that hypertension persists until the triggering 
stimulus is removed (see section 3.1).
Typically, AD is precipitated by noxious visceral or somatic stimulation below the level of 
injury that activates a massive sympathetic reflex causing widespread vasoconstriction. 
While the most common triggers are over-distension of the bowel or bladder (Canon et al., 
2015; Lindan et al., 1980; Snow et al., 1978), other noxious stimuli including skin 
lacerations, ingrown toenails, pressure sores, tight clothing and certain medical procedures 
such as bladder catheterization and cystometry are also reported to cause AD (reviewed in 
Karlsson, 1999). During an episode of AD, arterial blood pressure can reach devastating 
levels, with systolic values as high as 325 mmHg (McBride et al., 2003), exemplifying that 
AD is a hypertensive crisis that requires immediate medical attention (Muzumdar, 1982; 
Showkathali et al., 2007; Verghese, 1989). Severe cases that do not receive rapid and 
appropriate treatment can have serious consequences such as hypertensive encephalopathy, 
stroke, cardiac arrest, seizure and even death (Bjelakovic et al., 2014; Colachis et al., 1997; 
Eltorai et al., 1992;Fausel et al., 2014; Jain et al., 2013; Valles et al., 2005). Bouts of AD can 
arise multiple times daily due to the noxious yet unperceived afferent stimulation produced 
by normal, intermittent filling of the bladder and bowels (Fougere et al., 2016; Hubli et al., 
2015; Popok et al., 2016). In light of this, it is perhaps not surprising that eliminating AD is 
one of the highest priorities of the SCI population, based on a large national survey 
(Anderson, 2004) which reported that both quadriplegics and paraplegics prioritize the 
recovery of bowel/bladder function and elimination of AD over regaining walking 
movements, highlighting the need for research strategies to mitigate the development of AD 
altogether.
In this review, we provide a clinical description of AD along with its pharmacological 
management, and discuss the underlying pathophysiological changes that contribute to such 
dangerous, episodic hypertension after high-level SCI. We further describe recent studies 
revealing body-wide disturbances that result from chronic recurring episodes of AD, 
including vascular, cardiac and immunological dysfunctions. Contemporary research 
strategies will be considered to understand more comprehensively the underlying 
mechanisms, the full physiological impact of this syndrome that typically occurs multiple 
times daily, and potential therapeutic approaches to abrogate its development.
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2. Clinical Description of AD
2.1. Who is at risk for developing AD?
The T6 spinal segment is critical to the development of AD (Lindan et al., 1980;Mathias et 
al., 1988; Snow et al., 1978), as damage at or above this level interrupts descending 
modulation of the thoracolumbar SPN that regulate vasomotor tone, notably in the extensive 
splanchnic vascular bed (Blackmer, 2003; Gao et al., 2002). These vessels are innervated by 
the splanchnic nerves arising from the T5-T12 levels (Loukas et al., 2010) and receive 
approximately 25% of the cardiac output (Greenway et al., 1974; Rowell, 1990), which can 
have a large influence on total peripheral resistance and blood pressure. There are, however, 
uncommon reports of AD occurring after lesions below T6 but the magnitude of 
hypertension and changes in heart rate tend to be relatively mild since some degree of 
control over splanchnic sympathetic outflow remains intact (Moeller et al., 1973).
Not all individuals with SCI at or above the T6 level develop AD, with the prevalence 
reported between 48% and 91% (Curt et al., 1997; Lindan et al., 1980; Snow et al., 1978). 
This discrepancy is likely attributed to differences in the completeness of SCI, time elapsed 
since injury, and differences in the criteria used to confirm the presence of AD used among 
studies (Furusawa et al., 2011). Indeed, the clinical definition of AD is somewhat 
inconsistent (see section 2.2). Interestingly, AD has been documented in cases of non-
traumatic abnormalities of the spinal cord such as intramedullary astrocytoma (Furlan et al., 
2003) and multiple sclerosis (Kulcu et al., 2009), indicating that disruption of descending 
vasomotor pathways in any manner may contribute to the development of this syndrome.
2.2. Characteristic features of AD
The magnitude of hypertension required to be considered AD varies across studies. Snow et 
al. (1978) classified AD in adults as an increase of 40 mmHg systolic blood pressure 
whereas Popok et al. (2016) defined AD as an increase of 20 mmHg systolic blood pressure. 
Others (Lindan et al., 1980) diagnosed AD as a sudden rise in both systolic and diastolic 
blood pressure of any magnitude. Veteran’s Affairs guidelines recommend that AD in adults 
is considered following abrupt elevation in systolic blood pressure of 20–40 mmHg above 
baseline, whereas in pediatric SCI an increase of 15–20 mmHg systolic pressure warrants 
consideration (Canon et al., 2015; Consortium for Spinal Cord, 2002).
In addition to elevated blood pressure, individuals with an acute episode of AD can 
experience a diverse set of symptoms including debilitating headache, sweating, flushing of 
the skin above the injury level, piloerection, stuffy nose, blurred vision and anxiety 
(Karlsson, 1999). While these symptoms are not simultaneously present in all cases, 
headache and sweating above the lesion occurs 88% of the time (Lindan et al., 1980). 
Although the classical definition of AD is acute hypertension coincident with bradycardia 
(Erickson, 1980; Guttmann et al., 1947; Trop et al., 1991), the importance of heart rate in the 
diagnosis of AD is a matter of controversy. Lindan et al. (1980) reported an equal incidence 
of bradycardia and tachycardia (increase in heart rate) in documented cases of AD, whereas 
others report that tachycardia is more common (Hickey et al., 2004; Kewalramani, 1980; 
Scott et al., 1978). Whether an episode of AD is concomitant with an increase or decrease in 
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heart rate may depend on the injury level (Collins et al., 2006; Karlsson, 1999; Krassioukov 
et al., 2003). As suggested by Karlsson (1999), activation of sympathetic circuits in the 
spinal cord below a cervical injury may propagate rostrally towards cardiac-innervating SPN 
(i.e., T1-T4), explaining why tachycardia is frequently observed during AD. However, the 
correlation between injury level and the direction of heart rate change during episodes of AD 
has not been formally investigated.
2.3 Temporal development of AD after injury
AD most often presents in the chronic phase of SCI, with a majority of cases first occurring 
3–6 months after injury in humans (Lindan et al., 1980). While it may also occur in earlier 
stages of injury, the incidence of early AD is relatively low, with only 5.7% of individuals 
with SCI above T6 having clinically documented AD within the first month post-injury 
(Krassioukov et al., 2003). Though uncommon, the manifestation of AD in the early stage of 
injury is significant considering that treatment of acute, high-level SCI often includes 
pressor agents to help combat the profound hypotension associated with such injuries 
(reviewed in Ploumis et al., 2010). In cases of acute AD occurring within days of injury, 
systolic blood pressure as high as 210 mmHg has been reported (Silver, 2000), suggesting 
that concurrent vasopressor support may compound damage during episodic hypertension.
In experimental SCI, the development of telemetric monitoring techniques, along with the 
advent of computer algorithms capable of processing large amounts of hemodynamic data, 
have allowed for detailed analysis of the temporal development of AD in conscious animals 
(Laird et al., 2006; Mayorov et al., 2001; Rabchevsky et al., 2012; West et al., 2015). In both 
rats and mice with high-thoracic SCI, spontaneous AD triggered by naturally occurring 
stimuli emerges in a biphasic pattern with a transient surge of events occurring within the 
first week, followed by a gradual rise in frequency beginning around 2-weeks post-injury 
(Rabchevsky et al., 2012; West et al., 2015; Zhang et al., 2013). Moreover, the magnitude of 
change in systolic pressure during these events increases over time (West et al., 2015). These 
observations generally correspond to the development of AD in humans, where the initial 
disruption to descending vasomotor pathways allows for early AD (Krassioukov et al., 2003) 
before maladaptive changes in viscerosympathetic circuitry associated with more frequent 
and severe cases occur during the more chronic stages (West et al., 2015). Recent 
capabilities of screening ambulatory blood pressure recordings for daily AD events in 
humans (Hubli et al., 2014; Popok et al., 2016) will enable detailed analyses of the temporal 
progression of this syndrome in humans, as well as the efficacy of drugs to reduce the 
frequency or magnitude of recurrent AD.
3. Mechanisms contributing to AD
3.1. Loss of supraspinal control over sympathetic preganglionic neurons
Within the intact nervous system, supraspinal vasomotor neurons residing in the 
paraventricular nucleus, rostral ventrolateral medulla, rostral ventromedial medulla, caudal 
raphe nuclei and A5 cell group (Calaresu et al., 1988; Chalmers et al., 1994; Hosoya et al., 
1991; Jansen et al., 1995; Llewellyn-Smith, 2009; Strack et al., 1989; Sved et al., 2001) send 
projections to the intermediolateral cell column (IML), which is comprised of spinal nuclei 
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containing sympathetic preganglionic neurons (SPN) that extends throughout the T1-L2 
segments (Pyner et al., 1994; Tang et al., 1995; Zagon et al., 1993). These supraspinal 
neurons modulate the tonic firing of SPN which, in turn, send projections to the peripheral 
sympathetic chain ganglia or directly to the adrenal medulla (see Figure 1). The sympathetic 
ganglia act as the final sympathetic effector cells and innervate blood vessels throughout the 
body, whereas stimulation of the adrenal medulla secretes epinephrine and norepinephrine 
(NE) into the circulation. Together, this provides both direct and indirect control of blood 
vessel diameter and peripheral resistance to facilitate hemodynamic homeostasis (reviewed 
in Thomas, 2011).
After high-level SCI, the descending autonomic pathways responsible for supraspinal 
modulation of SPN become interrupted, reducing sympathetic tone below the injury 
(Stjernberg et al., 1986) and leaving SPN under the control of spinal influences alone. In the 
initial “spinal shock” phase of injury, which can last for weeks in humans (Ditunno et al., 
2004), this loss of descending control manifests as significantly reduced blood pressure and 
depression of sympathetic reflexes (Frankel et al., 1972). Over time, however, plasticity of 
SPN and reorganization of spinal circuitry create a hyper-excitable state that contributes to 
the aberrant reflex activation of SPN in response to afferent stimulation (see Figure 1) 
(Krassioukov et al., 2002;Llewellyn-Smith et al., 2001; Rabchevsky, 2006). Because of the 
interruption to descending modulatory pathways, which would normally inhibit the SPN 
during hypertension via the baroreflex (Guyenet et al., 1981), AD persists until the stimulus 
is withdrawn.
3.2 Synaptic reorganization of sympathetic preganglionic neurons (SPN)
The damage to descending vasomotor pathways caused by SCI leaves many SPN partially 
denervated, causing a number of histological and functional changes in these neurons in both 
the human and rat (Krassioukov et al., 1999; Krassioukov et al., 1995; Krassioukov et al., 
1996). Whereas SPN activity is normally regulated by a confluence of supraspinal and 
intraspinal inputs, their ongoing activity after complete SCI depends solely on the influence 
of spinal sympathetic interneurons (Schramm, 2006). Spinally derived sources of input to 
SPN include interneurons residing in laminae V, VII and X (Cabot et al., 1994; Cano et al., 
2001; Clarke et al., 1998; Deuchars et al., 2001;Deuchars et al., 2015; Joshi et al., 1995; 
Tang et al., 2004a). While there are no direct synaptic inputs to SPN from primary afferents, 
it is thought that sensory neurons can influence the SPN via such spinal interneurons 
(Laskey et al., 1988; Schramm, 2006). The integration of supraspinal and intraspinal inputs 
on SPN is complex and involves both monosynaptic and polysynaptic pathways (reviewed in 
Deuchars et al., 2015).
After experimental T4 spinal cord transection in adult rats, profound morphological changes 
occur to SPN within the IML below the lesion. Within 3 days of injury, the dendritic length 
and diameter of SPN soma decrease dramatically in response to the degeneration of 
terminals with supraspinal origins (Llewellyn-Smith et al., 2001). By two-weeks, however, 
the somatic size and dendritic arbor of SPN appears normal again (Krassioukov et al., 1996; 
Krenz et al., 1998a). These dynamic changes in gross SPN morphology correspond 
temporally with the evolution of cardiovascular dysfunction in rats with high-level SCI, 
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where pronounced resting hypotension occurs in the first days, followed by a gradual 
increase in basal blood pressure and the appearance of recurrent AD by two weeks post-
injury (Laird et al., 2006; Mayorov et al., 2001; Rabchevsky et al., 2012; West et al., 2015).
While atrophied SPN regain a normal morphology in the weeks after injury, experimental 
evidence suggests that a radical reorganization of synaptic inputs controlling their activity 
occurs. Weaver et al. (1997) demonstrated altered expression patterns of GAP-43 (growth 
associated protein-43), a marker of reactive sprouting, in both mature axons and growth 
cones in close apposition to SPN caudal to a complete mid-thoracic transection weeks after 
injury. Because of the complete transection model used and absence of degenerating 
supraspinal axons in the IML after 7 days, the source of these GAP-43 immunoreactive 
axons was limited to spinal neurons below the injury, suggesting reorganization of 
intraspinal sympathetic circuits that may contribute to the exaggerated sympathetic reflex 
during an AD event. Llewellyn-Smith et al., (2001) also observed a switch in the ratio of 
synapses on SPN containing glutamate or γ-aminobutyric acid (GABA), indicating a shift in 
the balance of excitatory and inhibitory influences, respectively. Specifically, Transection 
caused a decrease in the percentage of glutamatergic inputs versus an increase in the 
percentage of GABAergic inputs on SPN in the IML at the T8 spinal level after two-weeks, 
implying a predominantly inhibitory synaptic integration. While this observation is 
consistent with the resting hypotension and reduced sympathetic outflow seen after SCI, 
how this relates to the intense sympathetic outbursts that occur in response to noxious 
visceral stimulation is uncertain. Recent work by Huang et al. (2016) indicates that complete 
high-thoracic (T2) spinal cord transection in rats causes GAB A neurotransmission to 
convert from an inhibitory to excitatory role in nociceptive circuits. While the influence of 
SCI on GABAergic regulation of SPNs was beyond the scope of this work, it provides 
evidence that GABAergic inputs onto SPN may provide excitatory drive after SCI 
(Rabchevsky, 2006).
An alternative explanation may be that glutamatergic synapses on SPN are the predominate 
input recruited by noxious visceral stimulation. It has been documented that glutamatergic 
signaling through both NMDA and AMPA receptors is important for the initiation of AD in 
response to noxious colorectal distension (CRD) (Maiorov et al., 1997). Ueno et al. (2016) 
recently demonstrated that chemogenetic silencing of Vglut2+ (vesicular glutamate 
transporter 2) interneurons after T3 SCI suppressed anti-inflammatory sympathetic reflexes 
related to AD (see section 5.2). This is further supported by studies testing the anti-epileptic 
and neuropathic pain medication gabapentin (GBP) as an experimental treatment for AD 
(Rabchevsky et al., 2011). GBP is known to inhibit pre-synaptic glutamate release by 
binding to the a251 subunit of voltage-gated calcium channels (Coderre et al., 2005; Coderre 
et al., 2007; Gee et al., 1996; Shimoyama et al., 2000) and has been shown to reduce both 
the magnitude and frequency of AD in rats with complete Transection, specifically after 
acute but not chronic administration (Rabchevsky et al., 2011; Rabchevsky et al., 2012). 
Notably, however, the site(s) of action and mechanism(s) through which GBP mitigates AD 
remains uncertain. It is feasible that GBP acts by reducing glutamatergic transmission at the 
level of both primary afferents entering the spinal cord as well as glutamatergic spinal 
interneurons synapsing with SPN. GBP has also been reported to inhibit excitatory 
synaptogenesis both in-vitro and in-vivo by blocking the binding of synaptogenic 
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thrombospondin proteins to the a251 subunit (Eroglu et al., 2009). This suggests that GBP 
may work to reduce aberrant excitatory synapse formation in viscerosympathetic circuits 
after SCI. However, the short 2–3 hour half-life of GBP in rats (Radulovic et al., 1995; 
Vollmer et al., 1986) likely explains why once daily GBP treatment is insufficient to 
significantly reduce the frequency of spontaneous AD in the hours following administration; 
and likely insufficient to alter putative synaptic formation (Rabchevsky et al., 2012). Further 
studies into the synaptic mechanisms controlling SPN during noxious stimulation, as well as 
the precise means through which GBP mitigates AD may help identify novel therapeutic 
targets for prophylactically preventing the development of this syndrome.
3.3 Primary afferent sprouting
Intraspinal sprouting of primary afferent nociceptive fibers is also thought to contribute to 
the development of AD. After experimental SCI, the central arbors of unmyelinated c-fiber 
afferents expressing calcitonin gene-related peptide (CGRP), a marker of nociceptive fibers, 
sprout into the dorsal horn caudal to the injury (Hou et al., 2009; Krenz et al., 1998b). The 
extent of CGRP+ fiber sprouting into the lumbosacral spinal cord correlates with the 
magnitude of AD elicited by noxious CRD (Cameron et al., 2006; Krenz et al., 1999), 
suggesting that enhanced sprouting of nociceptive fibers increases reflex activation of SPN 
through propriospinal “relay” neurons (Figure 1, see section 3.4). Increased CGRP+ fiber 
density becomes apparent two weeks after experimental injury (Hou et al., 2009; Krenz et 
al., 1998b), a time at which AD develops reliably in spinal rats (Krassioukov et al., 1995; 
Laird et al., 2006). Importantly, increased CGRP+ fiber sprouting in the dorsal horn is also 
seen in the chronic stages of human SCI, and in one case has been associated with a well-
documented history of AD (Ackery et al., 2007).
The sprouting of c-fibers appears to be primarily dependent on nerve growth factor (NGF) 
signaling. After transection or contusion SCI, resident neurons and glia upregulate the 
expression of intraspinal NGF rostral and caudal to the lesion (Bakhit et al., 1991; Brown et 
al., 2004). Blockade of NGF signaling through intrathecal delivery of anti-NGF antibodies 
for two-weeks after T4-transection SCI effectively mitigates injury-induced sprouting of 
CGRP+ fibers throughout the spinal cord. Furthermore, animals receiving anti-NGF therapy 
had less severe AD in response to noxious CRD (Krenz et al., 1999), although this treatment 
did not abolish it completely. Cameron et al. (2006) used a proof-of-principle approach to 
overexpress NGF in the cord after T4-transection using adenovirus injections into either the 
T13/L1 or L6/S1 spinal levels innervating the distal colon and found that the pressor and 
bradycardic responses to CRD were significantly exacerbated. Conversely, injured cords 
injected with adenovirus encoding semaphorin 3a, a specific chemorepellant for both c-
fibers and sympathetic fibers (Tang et al., 2004b), had significantly diminished pressor and 
bradycardic responses during CRD. Such exacerbations or ameliorations were significantly 
correlated with increased or decreased CGRP+ fiber sprouting, respectively.
3.4 Propriospinal plasticity
Plasticity of ascending lumbosacral propriospinal fibers that relay pelvic sensory 
information rostrally towards SPN in the thoracic cord is also thought to contribute to the 
development of AD. There is compelling evidence for functional plasticity of propriospinal 
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interneurons which comprise spinal sympathetic circuits after transection SCI in the rat. 
Krassioukov et al. (2002) investigated the response of sympathetically-correlated 
interneurons to both noxious and innocuous stimuli hours following T3 transection (acute) 
as well as after one month (chronic). In the chronic but not acute stage of injury, 
interneurons whose electrical activity was cross-correlated with that of simultaneously 
recorded renal sympathetic nerve activity were excited by noxious CRD and cutaneous 
pinching, as well as non-noxious brushing of the skin caudal to the injury. This seminal 
study showed that in the weeks after injury, plasticity occurs within somatosensory relay 
neurons that influence the activity of SPN.
This electrophysiological evidence was supported histologically following anterograde 
tracer injections into the lumbosacral cord after complete T4-transection which significantly 
increased labeling of ascending propriospinal fibers originating in the dorsal gray 
commissure (DGC), notably found in juxtaposition to thoracic SPN labeled with Fluorogold 
(Hou et al., 2008). The DGC is a region in which pelvic visceral afferents terminate and 
send relay projections rostrally toward supraspinal targets (Al-Chaer et al., 1996; Hosoya et 
al., 1994; Matsushita, 1998; Pascual et al., 1993; Vizzard, 2000). Hou et al. (2008) found 
that a single session of prolonged, intermittent CRD performed two weeks after injury 
caused enhanced neuronal activation throughout the lumbosacral DGC, as indicated by 
increased expression of the immediate early gene c-fos in comparison to sham animals in 
which intact descending modulation prevents such expression. It remains unclear, however, 
whether the DGC neurons project directly to SPN or whether they project to excitatory 
interneurons to indirectly modulate the excitability of SPN (Rabchevsky, 2006).
Collectively, these findings support a model of AD in which plasticity of ascending 
propriospinal fibers, in conjunction with sprouting of primary afferents, creates an 
amplification of afferent stimuli below the injury such that noxious inputs are more likely to 
activate SPN to initiate unmodulated sympathetic reflexes resulting in an episode of AD 
(Figure 1). Previous technical limitations made it difficult to directly test the 
neuroanatomical basis of the AD reflex in live animals. However, with the recent 
development of elegant genetic and chemogenetic silencing techniques (Kinoshita et al., 
2012; Stachniak et al., 2014; Zhu et al., 2014), it may now be feasible to directly assess the 
role of specific populations of ascending propriospinal neurons in conveying lumbosacral 
afferent input to rostral segments containing cardiovascular SPN (Figure 1, see section 6).
3.5 Peripheral adrenergic hypersensitivity
In addition to maladaptive plasticity of viscerosympathetic circuitry, there is also evidence of 
peripheral changes responsible for the exaggerated pressor response to afferent stimulation. 
In quadriplegics, resting blood pressure and plasma catecholamine levels are both 
significantly lower than in intact subjects (Mathias et al., 1976). This is consistent with the 
observation that sympathetic outflow below the lesion is lower both acutely and chronically 
after SCI (Mathias et al., 1979; Wallin et al., 1984), which would be expected to produce 
lower concentrations of circulating catecholamines (Goldstein et al., 1983). However, it has 
been demonstrated that the vasomotor response to intravenously infused NE is enhanced in 
quadriplegics with a documented history of AD. Specifically, by measuring the diameter of 
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the dorsal foot vein before and after local intravenous administration of NE, Arnold et al. 
(1995) found that the concentration of NE required to induce a 50% reduction in resting 
vessel diameter was significantly lower in tetraplegics compared to normal controls (1.6 
mg/min vs. 10.9 ng/min). Similarly, Krum et al. (1992b) found that the dose of intravenously 
infused phenylephrine (a peripheral α1-adrenergic receptor agonist) required to produce a 
pressor response of 20 mmHg is significantly lower in functionally complete quadriplegics 
compared to normal individuals. Furthermore, Krum et al. (1992a) reported that even modest 
increases in plasma NE during bladder cystometry after high-level SCI were sufficient to 
produce a significant pressor response greater than 20 mmHg systolic. Taken together, these 
studies indicate that SCI promotes hypersensitivity of the vasculature to catecholamines 
released through aberrant, unmodulated sympathetic reflexes, and that this 
hypersensitization may contribute to the severity of episodic hypertension after SCI.
There is indication that peripheral sensitization following SCI is limited to the vasculature 
caudal to the lesion and not within rostral vascular beds in which central sympathetic control 
remains intact. Following T4 transection in rats, Rummery et al. (2010) found evidence of 
enhanced neurovascular transmission in the saphenous artery which receives sympathetic 
outflow from the lower thoracolumbar cord. However, SCI-related neurovascular 
potentiation was not seen in the median artery which receives sympathetic outflow from the 
cord rostral to the lesion. Brock et al. (2006) similarly found that T4 transection in rats leads 
to increased neurovascular transmission within the mesenteric vasculature, with perivascular 
nerve stimulation producing five-fold increased contractions of mesenteric arteries seven 
weeks after SCI. This increased reactivity of mesenteric arteries was blunted by the 
adrenergic antagonist prazosin, further implicating that peripheral hypersensitization is 
secondary to changes in adrenergic transmission after injury. While the mechanism of this 
phenomenon is not fully known, Brock et al. (2006) suggest that decreased norepinephrine 
reuptake may be a contributing factor. Alternatively, Al Dera et al. (2012) report that 
complete SCI in rats also alters L-type calcium channels, with their activation playing a 
larger role in smooth muscle contraction of tail arteries isolated after injury. Whether or not 
these two mechanisms are unique to specific vascular beds caudal to the lesion remains 
unclear.
Consistent with the hypothesis that SCI causes enhanced adrenergic sensitivity in peripheral 
vasculature, Lee et al. (2016) demonstrated increased protein expression of the α1-
adrenergic receptor in the femoral artery of rats after T10 spinal contusion. Furthermore, this 
increased receptor expression corresponded to an enhanced pressor response and 
vasoconstriction of isolated femoral arteries in response to phenylephrine stimulation. 
Whether or not the time-course of these changes corresponds to the timeline over which AD 
develops in rodents or humans remains unknown. Moreover, it is unclear whether these 
findings are applicable to AD since this syndrome does not develop after T10 contusion SCI. 
Although there is compelling evidence that peripheral sensitization is important in the 
pathophysiology of AD, many questions remain regarding the underlying cellular processes 
and time-course over which adrenergic hyper-responsiveness develops, as well as the relative 
contribution compared to central maladaptive plasticity discussed.
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4. Clinical management of AD
A variety of non-pharmacological and pharmacological strategies can be used to treat AD. 
Since AD often resolves once the inciting stimulus is removed, the current standard of care 
recommends identifying and eliminating the inciting factors, when possible, before 
pharmacological approaches are considered (Consortium for Spinal Cord, 2002). Immediate 
measures involve assessment of resting arterial pressure and monitoring for other symptoms 
associated with AD (see section 2.2). If hypertension is observed, it is advised to move 
patients into an upright position to facilitate the lowering of arterial pressure through 
hydrostatic redistribution of blood to the lower extremities. This postural maneuver causes a 
reduction of blood pressure in high-level SCI patients (Krassioukov et al., 2006), although 
the efficacy to alleviate hypertension specifically during AD has not yet been formally 
investigated (Krassioukov et al., 2009). Since filling of the bladder and impaction of the 
bowel are the most common triggers of AD (Lindan et al., 1980), bladder voiding or bowel 
care routines should next be considered along with a general inspection for other possible 
sources of noxious stimulation such as pressure sores, tight clothing and skin laceration. 
Given that blood pressure can fluctuate rapidly in patients with AD, it is important to 
monitor blood pressure every 2–5 minutes for resolution or exacerbation of hypertension 
during physical examination (Consortium for Spinal Cord, 2002).
While some cases of AD are mild and resolve relatively easily, more severe cases can 
produce profound levels of hypertension and have no readily identifiable cause. 
Furthermore, it may be difficult to identify and remove the triggering stimuli, particularly for 
individuals with high thoracic and cervical injuries who have limited dexterity and mobility. 
Therefore, a variety of drugs and medical procedures have been employed for the control of 
AD, primarily through managing hypertension. Some of the most common remedies are 
briefly discussed below.
4.1 Nitrates
Organic nitrates, such as nitroglycerine paste, are currently the most commonly prescribed 
medications for mitigating acute episodes of AD (Braddom et al., 1991; Caruso et al., 2015). 
Nitrates are a class of drugs that are converted to or release nitric oxide (NO), an 
endogenous molecule that induces smooth muscle relaxation in the vasculature (Moncada et 
al., 1993). For acute episodes of AD, it is recommended to apply 2% nitroglycerin paste 
onto the skin above the level of SCI (Braddom et al., 1991). Vasodilation and subsequent 
reduction of blood pressure occurs rapidly after transdermal application and the paste can be 
wiped off once the therapeutic effect has been achieved (Grobecker, 1990). Moreover, a 
variety of oral and transdermal patch preparations are available and easy for patients and 
caregivers to administer. In severe cases of AD that are difficult to control, notably in a 
clinical setting, intravenous sodium nitroprusside may also be used to rapidly resolve 
hypertension (Valles et al., 2005).
4.2 Nifedipine
Nifedipine is an L-type calcium (Ca2+) channel blocker that reduces the influx of Ca2+ into 
vascular smooth muscle cells, leading to a reduction in peripheral resistance and 
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consequently blood pressure. Despite few controlled clinical trials, nifedipine has been 
widely used to treat AD in SCI patients (Braddom et al., 1991; Caruso et al., 2015; Dykstra 
et al., 1987; Esmail et al., 2002; Krassioukov et al., 2009; Thyberg et al., 1994). In a survey 
of clinicians with extensive experience treating AD, Braddom et al., 1991) found that 
nifedipine was the most commonly prescribed agent to manage minor or severe symptoms of 
AD. More recently, nitrates have become slightly more prominent than nifedipine in treating 
minor or severe episodes of AD (Caruso et al., 2015), likely stemming from safety concerns 
regarding the use of nifedipine during hypertensive crises because it may overshoot the 
therapeutic drop in blood pressure and cause severe hypotension and ischemia (Chobanian et 
al., 2003). Although there are no formal descriptions in the literature of adverse effects 
related to the use of nifedipine specifically for AD, it is possible that it may reduce arterial 
pressure below the range for critical renal, cerebral and cardiac vascular beds to autoregulate 
their perfusion, particularly since many with AD are predisposed to resting and orthostatic 
hypotension (Furlan et al., 2008).
4.3 Prazosin
The adrenergic receptor antagonist, prazosin, is another drug used to treat AD (Krum et al., 
1992c; Phillips et al., 2015). Prazosin is an antihypertensive agent that works by specifically 
blocking α1-adrenergic receptors located on peripheral vasculature (Cavero et al., 1980). 
Unlike other hypertension medications, prazosin has little effect on cardiac function or 
resting blood pressure (Jaillon, 1980), making it safer to use in patients with chronic 
hypotension. Krum et al. (1992c) reported that, compared to placebo treatment, twice daily 
prazosin significantly decreased the magnitude of hypertension and severity of secondary 
symptoms during AD caused by a variety of genitourinary and colorectal stimuli. More 
recently, Phillips et al. (2015) reported that prazosin reduced the magnitude of hypertension 
during AD during sperm retrieval procedures involving penile vibrostimulation, which is a 
well-documented cause of AD. Collectively, research on the use of prazosin indicates that it 
may be useful as a prophylactic treatment for AD triggered by a variety of iatrogenic stimuli 
(Krum et al., 1992c; Phillips et al., 2015) .
4.4 Botulinum Toxin
Conservative pharmacological approaches are not always effective, and some individuals 
require more aggressive treatments (Krassioukov et al., 2009). One such treatment is 
botulinum toxin (BTX), a neurotoxin derived from Clostridium botulinum that suppresses 
neuromuscular transmission by cleaving synaptic proteins required for neurotransmitter 
exocytosis (reviewed in Dolly, 2003). Due to its ability to temporarily cause detrusor muscle 
paralysis by preventing parasympathetic post-ganglionic acetylcholine release, delivery of 
BTX into the detrusor muscle has been used to treat bladder dysfunction secondary to SCI, 
such as neurogenic detrusor overactivity (NDO) (Dykstra, 2003; Dykstra et al., 1988; 
Orasanu et al., 2013; Schurch et al., 2005). As these conditions disrupt normal micturition 
and can lead to noxious distension of the bladder, they are associated with the occurrence of 
AD. While there have been no large-scale clinical trials for BTX as a prophylactic treatment 
of AD, there is indication that this could be a safe and tenable approach to minimize AD 
associated with bladder dysfunction and certain medical procedures such as cystoscopy. 
Schurch et al. (2000) reported a disappearance of AD caused by bladder voiding in a small 
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subset of patients receiving BTX injections into the detrusor muscle to treat neurogenic 
bladder, though the duration of this improvement was not specified. Recently, Fougere et al. 
(2016) conducted a small clinical trial specifically to assess the efficacy of intradetrusor 
injections of BTX to reduce bladder-related AD and observed a decrease in the severity of 
AD during cystometric filling of the bladder. Moreover, ambulatory blood pressure 
recordings revealed a decrease in the frequency of daily bladder-related AD for at least one 
month, accompanied by an increase in quality of life measures. Such reports indicate that 
BTX treatment may be a safe and potentially long-lasting means of prophylactically treating 
bladder-related AD. Notably, the duration of effect after BTX treatment is limited due to a 
combination of compensatory sprouting of peripheral nerve terminals and the gradual 
recovery of synaptic proteins necessary for neurotransmitter release (Dolly, 2003). While the 
duration of detrusor paresis is approximately 9 months (Schurch et al., 1996), it remains 
unknown how long intradetrusor BTX treatment can provide relief of AD.
In addition to temporary paralysis of bladder smooth muscle, there is also evidence that 
BTX treatment reduces AD by modulating sensory transmission into the spinal cord. 
Apostolidis et al. (2005) reported that intradetrusor injections of BTX in patients with NDO 
caused a decrease in the expression of both purinoceptors (P2X3) and capsaicin receptors 
(TRPV1) in sensory fibers innervating the bladder, and that this decrease was correlated 
temporally with a significant improvement in bladder function. These receptors are involved 
in bladder nociception (Birder et al., 2002; Cockayne et al., 2000), suggesting that decreased 
afferent signaling contributes to the improvement in urodynamic function after BTX 
treatment. In an experimental model, Elkelini et al. (2012) instilled BTX into the bladder of 
rats after T4-transection and observed a significant reduction in the magnitude of AD 
induced by bladder distension during cystometry, which was associated with reduced NGF 
expression in the bladder and sensory neurons in the dorsal root ganglia. As NGF regulates 
c-fiber density in the bladder (Schnegelsberg et al., 2010), it is also possible that BTX 
reduces bladder-related AD by decreasing the innervation or distribution of nociceptive 
fibers. Notably, intradetrusor BTX treatment has also been used to alleviate refractory AD in 
a pediatric SCI patient (Lockwood et al., 2016).
5. Systemic effects of recurrent AD
5.1 Cardiovascular Changes
Emerging evidence suggests that the recurrence of AD, which can occur more than 40 times 
a day for some individuals (Hubli et al., 2015), adversely affects multiple physiological 
systems over time. Alan et al. (2010) demonstrated that repeated instances of AD after 
experimental SCI exacerbate injury-induced peripheral vascular dysfunction. Isolated 
mesenteric arteries from rats which underwent 30-minutes of continuous CRD daily for two-
weeks after T3 transection SCI had a more pronounced vasoconstrictor response to 
phenylephrine (an α1-adrenergic agonist) compared to arteries from animals with SCI only. 
This suggests that injury-induced adrenergic hypersensitization, which itself is a mechanism 
involved in the etiology of AD (see section 3.5), is exacerbated by repeated instances of AD 
and may help explain why the severity of AD increases over time (West et al., 2015). If this 
is the case, it should be possible to dampen the temporal increase in AD severity by 
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pharmacologically controlling adrenergic hypersensitization. However, as discussed in 
section 3.5, the cellular processes leading to adrenergic hyper-responsiveness have yet to be 
elucidated.
Repetitive surges in blood pressure from recurrent AD may also induce maladaptive 
structural changes in peripheral vasculature (West et al. (2013). Vascular remodeling is a 
dynamic process that responds to changes in shear stress from normal hemodynamic 
fluctuations as well as hypertensive disease (Baeyens et al., 2015; Schiffrin, 2004; Silver et 
al., 2006). While SCI alone is associated with changes in vascular structure, this is believed 
to be an adaptation to the decreased metabolic demands of atrophied tissue below the injury 
(Olive et al., 2003). The hypothesis that blood pressure fluctuations from recurrent AD cause 
further remodeling of peripheral vasculature requires additional study, particularly since 
structural changes to resistance vessels, such as alterations in the ratio of wall thickness/
lumen diameter, are strongly associated with cardiovascular disease (Rizzoni et al., 2003).
Deleterious changes in cardiac function are also associated with daily repeated bouts of 
experimental AD. West et al. (2016) investigated the effects of recurrent AD on cardiac 
structure and function in rats following T3 transection. Beginning 2-weeks after injury, rats 
received 60-minutes of repetitive CRD daily for 4 weeks. In-vivo echocardiography revealed 
that animals with daily induced AD (SCI-AD) had diminished basal contractility and their 
hearts developed significantly lower left ventricular pressure with a slower rate of ventricular 
contraction. These alterations in cardiac mechanics were accompanied by a dampened 
inotropic response to β-adrenergic stimulation during isoproterenol challenge in the SCI-AD 
group compared to SCI alone, despite no differences in β-adrenergic receptor expression. 
Taken together, this data suggests that recurrent AD leads to aberrant cardiac mechanics, 
which may be due to desensitization of adrenergic receptors in the heart. Notably, these 
experimental findings were corroborated with clinical data which indicated a relationship 
between the number of daily AD events and impaired cardiac mechanics in a small sample 
of humans with mid-cervical SCI (C4-C8). As suggested by the authors (West et al., 2016), 
this consequence of recurrent AD may also contribute to the increased risk of cardiovascular 
disease in people with SCI (Cragg et al., 2013; Garshick et al., 2005).
In addition to peripheral vasculature, there are emerging reports of associations between AD 
and cerebrovascular function. Phillips et al. (2016b) found that high-thoracic SCI in rats 
causes maladaptive changes in middle cerebral artery (MCA) structure and function. Seven 
weeks after T3 transection, ex-vivo analysis of MCA revealed decreased vessel compliance 
and diminished vascular reactivity to vasoconstrictive 5-hydroxytryptamine. The functional 
changes in MCA preparations were seen in conjunction with increased collagen deposition 
and wall thickness, suggesting that arterial stiffening and structural remodeling after SCI 
may impair cerebral autoregulation. Considering that T3 transection in rats reliably causes 
AD to develop within two weeks, and given the seven-week duration of this study, it is likely 
that recurrent AD contributed to these findings. Potential changes in cerebrovascular 
function may help explain cognitive dysfunction which has been documented after high-
level SCI (Davidoff et al., 1990; Phillips et al., 2014; Wecht et al., 2013). Phillips et al. 
(2016a) provided preliminary data suggesting that cerebral autoregulation is capable of 
maintaining sufficient blood flow to the brain during mild and slowly evolving episodes of 
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AD, though it remains unknown if the cerebral vasculature can respond appropriately during 
more severe and rapidly occurring episodes. Ultimately, it will be important for future 
studies to determine whether recurrent AD causes structural and functional modifications to 
peripheral and cerebral vasculature since these maladaptations have been proposed to 
contribute to cardiovascular and cognitive dysfunction after SCI (Phillips et al., 2016b; 
Wecht et al., 2013).
5.2 Immunomodulatory effects of AD
In addition to cardiovascular anomalies, AD is linked to aberrant functioning of the immune 
system (Ueno et al., 2016; Zhang et al., 2013). Compared to the general population, people 
with chronic SCI have a weakened immune system capacity (Campagnolo et al., 1994; 
Iversen et al., 2000) and are more susceptible to lethal infections such as pneumonia 
(Brommer et al., 2016). This phenomenon, known as spinal cord injury-induced immune 
depression syndrome (SCI-IDS) (Riegger et al., 2007), is dependent on the level of SCI, 
with injuries above the level of the major sympathetic outflow being associated with more 
severe immunosuppression (Brommer et al., 2016; Campagnolo et al., 1997; Iversen et al., 
2000; Lucin et al., 2007; Zhang et al., 2013). Iversen et al. (2000) collected blood and bone 
marrow samples from individuals with SCI and observed diminished lymphocyte activity 
and impaired proliferation of hematopoietic progenitor cells, particularly in tetraplegics with 
mid-cervical injuries. Similarly, Lucin et al. (2007) found that T3 but not T9 transection in 
mice causes a loss of splenocytes and B cells in association with enhanced levels of splenic 
NE and blood cortisol levels.
In intact subjects, the immune system is modulated by the hypothalamic-pituitary-adrenal 
axis (HPA) and sympathetic nervous system (SNS) (reviewed in Irwin et al., 2011). In 
response to physical or psychological stress, the anterior pituitary gland releases 
adrenocorticotropic hormone to stimulate the release of glucocorticoids (GCs) from the 
adrenal cortex into the blood. There is also evidence for direct neural innervation of the 
adrenal cortex by SPN (Engeland et al., 2005), suggesting that sympathetic activity during 
AD may also promote GC release. GCs subsequently bind to the intracellular glucocorticoid 
receptor in leukocytes to alter the transcriptional programming and limit inflammatory 
responses (reviewed in Rhen et al., 2005). Additionally, activation of the SNS modulates the 
immune system through the release of NE directly into lymphoid tissues, where it binds to 
β2-adrenergic receptors on a variety of immune cells, including lymphocytes and 
macrophages. Like GCs, NE can have immunosuppressive effects on a variety of immune 
cells, including B and T lymphocytes, by activating intracellular signaling cascades such as 
the cyclic adenosine monophosphate (cAMP) pathway. Ultimately, the result of such 
stimulation is to shunt cellular activity away from a pro-inflammatory state (reviewed in 
Lorton et al., 2015).
Because of the immunosuppressive role of SNS stimulation, it is thought that SCI-IDS is 
caused by heightened sympathetic activity and catecholamine release during recurrent bouts 
of AD. Zhang et al. (2013) reported a causal link between AD and chronic 
immunosuppression. The temporal development of AD in mice with T3 transection SCI 
corresponded to an elevated level of circulating GCs and accumulation of NE within the 
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spleen, along with a profound loss of greater than 50% of splenic leukocytes by 5-weeks 
post-injury. Compared to sham operated or low thoracic (T9) SCI mice which do not 
develop AD, those with spontaneously occurring AD measured telemetrically and quantified 
with a computer detection algorithm had a limited capacity to produce antibodies after 
injection of immunogenic ovalbumin. Additionally, this immunodeficiency was exacerbated 
by experimentally inducing AD with repeated bouts of noxious CRD. The 
immunosuppressive effects associated with established AD were reversed after treating 
injured mice with a cocktail of a selective β2-adrenergic receptor antagonist and a GC 
receptor antagonist, concluding that immunosuppression after T3 SCI in mice is caused by 
AD-related elevations in NE and GC. Notably, however, this treatment cocktail was not 
reported to alter the occurrence of AD. These experimental findings in mice were 
corroborated with data from a mid-cervical SCI patient showing that tapping of the abdomen 
overlying the urinary bladder, which stimulated an episode of AD, caused an increase in 
catecholamine release with a concomitant reduction in lymphocyte proliferation (Zhang et 
al., 2013). More recently, Ueno et al. (2016) used an inducible chemogenetic silencing 
approach in mice with T3 SCI to inhibit glutamatergic interneurons thought to facilitate 
reflex activation of SPN innervating the spleen during AD. After silencing these neurons 
daily for 2-weeks, the quantity of splenic B and T cells was restored to pre-injury levels. 
Together, these studies may explain why people with high-level SCI, many of whom 
experience AD, have increased susceptibility to a variety of infectious diseases, and further 
implies that controlling or preventing AD is essential for overall well-being.
Importantly, the immunomodulatory effects of recurrent AD may only be a contributing 
factor to SCI-IDS rather than the primary driver. For example, direct sympathetic 
innervation of the bone marrow (Bjurholm et al., 1988; Denes et al., 2005) is thought to help 
regulate hematopoiesis and immune function in the normal, uninjured state (reviewed in 
Jung et al., 2017). Therefore, dysregulated activity of decentralized sympathetic fibers 
innervating bone marrow following SCI may also contribute to SCI-IDS. Moreover, it is well 
documented that SCI leads to decreased bone density as a result of diminished gravitational 
load (Biering-Sorensen et al., 1990; Zehnder et al., 2004). As the bone marrow is a major 
site of hematopoiesis, it is possible that bone atrophy after SCI compromises the 
hematopoietic niche, which may help to explain the reduced immune cell production seen 
after injury (Iversen et al., 2000). The relative contribution of these potential mechanisms 
warrants future investigation.
6. Emerging research strategies
Important questions remain regarding the underlying mechanisms responsible for episodic 
AD that develops after SCI. While strong correlative evidence supports a role in maladaptive 
plasticity of lumbosacral primary afferents and ascending propriospinal neurons, the relative 
contribution of these modified pathways to the AD syndrome is unclear. Recently developed 
genetic and chemogenetic neuronal silencing techniques should allow future investigations 
aimed at dissecting the precise role of these distinct neuroanatomical pathways. For 
example, Kinoshita et al. (2012) injected a complimentary set of viral vectors into regions of 
the spinal cord containing the terminals and soma of propriospinal neurons thought to be 
critical for the execution of dexterous hand movements. In their model, a highly efficient 
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retrogradely transported lentiviral vector carrying enhanced tetanus toxin (HiRET-eTeNT) 
under the control of the tetracycline-responsive element was injected into the spinal 
segments containing the terminals of their target neurons. In addition, a second adeno-
associated viral (AAV) vector carrying a reverse tetracycline transactivation sequence (AAV-
rtTAV) was injected into the spinal cord segment containing the cell bodies of those same 
neurons. With this approach, it was possible to silence neurons by inducing the expression of 
tetanus toxin through systemic delivery of doxycycline. Notably, only the neurons which 
were doubly infected with both HiRET-eTeNT and AAV-rtTAV were silenced, providing a 
reversible and spatially targeted method for investigating the role of specific neural 
pathways. Based on such an approach, it is potentially feasible to doubly infect and silence 
ascending propriospinal relay neurons which originate in the lumbosacral cord that project 
rostrally towards thoracic SPN to directly test their contribution to AD induced through 
stimulation of lumbosacral afferents (see Figure 1). As discussed in section 5.2, Ueno et al. 
(2016) employed a novel chemogenetic silencing approach to prevent the development of 
SCI-IDS associated with AD by blocking neurotransmission of glutamatergic spinal 
interneurons, though it is unknown whether this approach would also ameliorate 
hemodynamic changes during AD. Moreover, this method silenced all glutamatergic 
interneurons in the injected regions (T5-T7) and, therefore, does not allow for the precise 
dissection of specific intraspinal pathways.
Alternatively, a recent report by Iyer et al. (2016) demonstrated the ability to silence specific 
nociceptive primary afferents using a chemogenetic method in which AAV carrying the 
engineered inhibitory hMD4(Gi) DREADD receptor (designer receptor exclusively activated 
by a designer drug) was injected directly into the sciatic nerve. Upon activation with the 
highly specific ligand clozapine-n-oxide (CNO), the hMD4(Gi) receptor hyperpolarizes 
neurons through induction of the G-protein inward-rectifying potassium channel 
(Armbruster et al., 2007). They demonstrated that intraperitoneal injection of clozapine-n-
oxide (CNO) significantly increased mechanical and thermal nociceptive thresholds in the 
foot pads of animals with DREADD infected afferents. Because the genetic and 
chemogenetic silencing methods discussed here have distinct ligand-receptor interactions, it 
may be possible within a single animal to serially silence propriospinal relay neurons and 
primary afferents to directly investigate their contributions to both spontaneous and CRD-
induced AD.
In addition to further mechanistic studies, it will also be important to fully elucidate the 
systemic effects of recurrent AD. The metabolic consequences of sporadic, uncontrolled 
fluctuations in catecholamines and GCs released during AD are not well known. As 
suggested by Karlsson (1999), frequent daily bouts of AD accompanied with such abnormal 
surges in GCs and catecholamines may contribute to the high reported incidence of 
metabolic abnormalities in persons with SCI (Duckworth et al., 1980; Gorgey et al., 2014; 
Maruyama et al., 2008; Yekutiel et al., 1989). Considering that GC and catecholamines have 
a number of effects on energy metabolism in various tissues throughout the body, including 
the liver, spleen, pancreas, adipose tissue and skeletal muscle (reviewed in Barth et al., 2007; 
Vegiopoulos et al., 2007), it is possible that recurring AD predisposes or exacerbates the 
development of metabolic disease, such as insulin resistance and dyslipidemia. In support of 
this, Bluvshtein et al. (2011) reported that postprandial insulin resistance is present in 
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tetraplegics with cervical SCI, but not in paraplegics with thoracic SCI that preserves some 
level of supraspinal control over sympathetic outflow. Moreover, manual percussion of the 
abdomen overlying the bladder in people with high-thoracic or cervical SCI was found to 
activate lipolysis in tissues below the injury level in association with increased blood 
pressure and catecholamine release (Karlsson et al., 1997). Whether a relationship exists 
between the magnitude and frequency of AD and the incidence of insulin resistance or 
abnormal lipid metabolism has not yet been formally investigated.
7. Conclusions
AD can have a significant impact on the quality of daily living and, if not treated properly 
and timely, this hypertensive syndrome can have deleterious cardiophysiological and 
systemic consequences. The most common treatment paradigms involve vasoactive drugs 
intended to resolve the acute hypertensive crises rather than preventing them from occurring, 
though some evidence suggests that prazosin and botulinum toxin may provide prophylactic 
management of AD associated with normal and iatrogenic urogenital stimulation. While 
well documented, the intracellular signaling processes underlying adrenergic 
hypersensitization in the context of AD are unknown. Recent methodological advances 
should allow for more detailed investigation into the relative contribution of specific 
propriospinal neurons and primary afferent fibers to this aberrant viscerosympathetic reflex 
after SCI. The widespread physiological consequences of recurrent AD, which can happen 
dozens of times daily, have only recently been investigated. Animal models and clinical data 
indicate that repeated episodes of AD exacerbate peripheral adrenergic hypersensitization, 
suppress immune function, compromise cardiac mechanics, and potentially alter 
cerebrovascular and cognitive function. However, the potential effects of recurrent AD on 
peripheral and central vasculature structure, as well as widespread metabolism have only 
begun to be investigated. In light of recent data describing profound systemic effects of 
chronic AD, it is increasingly important to develop more targeted therapies capable of 
preventing the development of this syndrome and its associated maladies altogether in order 
to improve quality of lives for individuals with SCI who are predisposed to this syndrome.
Acknowledgments
Funding
This work was supported by SCoBIRC Chair Endowment (AGR), 5T32 NS077889 (KCE)
Glossary of acronyms
SCI spinal cord injury
AD autonomic dysreflexia
SCI-IDS spinal cord injury-induced immune depression syndrome
SPN sympathetic preganglionic neurons
IML intermediolateral cell column
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NE norepinephrine
BTX botulinum toxin
NDO neurogenic detrusor overactivity
NGF nerve growth factor
GABA gamma-aminobutyric acid
GBP gabapentin
CRD colorectal distension
SNS sympathetic nervous system
HPA hypothalamic pituitary axis
GC glucocorticoid
DREADD designer receptor exclusively activated by designer drug
CNO clozapine-n-oxide
DGC dorsal gray commissure
CGRP calcitonin gene related peptide
NMDA N-methyl-D-aspartate receptor
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
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Highlights
• Autonomic dysreflexia (AD) is defined as episodic hypertension and 
concomitant baroreflex-mediated bradycardia initiated by unmodulated 
sympathetic reflexes in the decentralized cord.
• Herein, we review the pathophysiological mechanisms underlying the 
development of AD, including maladaptive plasticity of neural circuits 
mediating abnormal sympathetic reflexes and hypersensitization of peripheral 
vasculature that collectively contribute to abnormal hemodynamics after SCI.
• Contemporary research avenues are presented to elucidate the effects of 
recurring AD on cardiovascular and immune functions for developing more 
targeted and effective treatments to attenuate the development of AD.
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Figure 1. 
Diagrammatic representation of the neuroanatomical circuitry thought to be involved in 
autonomic dysreflexia triggered by pelvic visceral stimulation, as well as potential neuronal 
pathway silencing paradigms. Descending vasomotor fibers (blue) originating in the 
brainstem and hypothalamus modulate the tonic activity of sympathetic preganglionic 
neurons (SPN; red) throughout the intermediolateral cell column (IML) in the thoracolumbar 
spinal cord. After complete spinal cord injury at or above the T6 segment, SPN which 
innervate the adrenal medulla and blood vessels below the injury are segregated from 
descending control pathways, allowing for unrestrained sympathetic reflex activity that leads 
to hypertension. Injury further leads to maladaptive sprouting of both primary afferent c-
fibers (purple) and ascending propriospinal tracts (green) originating in the lumbosacral 
dorsal gray commissure (DGC). These ascending “relay” neurons are thought to convey 
sensory information from the bladder and colon (i.e., distension) rostrally towards SPN. 
Emerging neuronal silencing techniques may allow for investigations into the role of specific 
neuroanatomical pathways involved in AD. One example might be to employ double 
infection of ascending lumbosacral propriospinal neurons with the HiRET-eTeNT vector 
(red syringe), which is retrogradely transported (dotted black lines) from nerve terminals in 
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the IML to lumbosacral DGC also infected with AAV-rtTAV vector (blue syringe). 
Doxycycline-induced silencing of these neurons could then allow for direct investigation 
into their roles in facilitating AD during pelvic visceral stimulation.
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